1. India Stocks

  2. •

    Process industries

  3. •

    Chemicals: agricultural
Aristo Bio Tech and Lifescience Limited

Aristo Bio Tech and Lifescience Limited

NNSE:ARISTO
86.00
INR
-2.20
(-2.49%)
791.07MMarket Cap
Aristo Bio Tech and Lifescience Limited
NSE:ARISTO
(National Stock Exchange of India)

Recent

price

86.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2020
2021
2022
2023
2024
2025
2026
TTM
INR
345.93
288
243.12
410.97
360.1
467.25
534.27
- -
Revenue per Share
1.48
1.58
2.11
6.72
5.72
5.97
10.55
- -
Basic EPS, GAAP
-1.17
0.43
5.18
-12.91
1.54
7.21
9.17
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
0.65
0.5
0.6
- -
Dividend per Share
18.08
19.66
21.84
44.3
49.37
54.84
64.79
54.84
Book Value per Share
18.07
19.65
21.83
44.29
49.37
54.83
64.79
54.83
Tangible Book Value per Share
7
7
7
5
7
7
7
7
Basic Weighted Avg Shares
2,355
1,961
1,655
2,179
2,451
3,181
3,637
- -
Sales/Revenue/Turnover
1.69
2.06
3.05
3.29
2.96
2.16
3.61
- -
Operating Margin (%)
5
7
11
15
16
26
29
- -
Depreciation Expense
10
11
14
36
39
41
72
- -
Net Income, GAAP
27.84
28.19
27.6
24.83
27.96
25.68
25.93
- -
Effective Tax Rate (%)
0.43
0.55
0.87
1.64
1.59
1.28
1.97
- -
Profit Margin (%)
118
131
116
232
215
202
267
202
Working Capital
107
121
111
102
100
76
76
76
LT Debt
123
134
149
302
336
373
441
373
Total Equity
- -
7.55
7.71
11.38
9.63
8.87
13.68
- -
Return on Invested Capital (%)
- -
7.87
7.36
11.23
9.94
9.77
13.05
- -
Return on Capital (%)
- -
8.38
10.15
15.82
12.22
11.46
17.64
- -
Return on Common Equity (%)

Capital Structure

INR

•

in mil. unless spec.
Mar'24
Sep'25
Mar'25
ST Debt
109
118
142
LT Borrowings
100
85
76
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
7
7
7
Market Capitalization
425
821
791

Working Capital

INR

•

in mil. unless spec.
Mar'24
Sep'25
Mar'25
Total Current Assets
1,051
1,995
1,158
Cash, Cash Equivalents & STI
6
8
11
Accounts Receivable, Net
575
1,423
562
Inventories
402
447
474
Total Current Liabilities
836
1,763
956
Payables & Accruals
- -
- -
- -
ST Debt
109
118
142
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
30.93%
18.15%
Free Cash Flow
- -
216.96%
27.15%
Net Income, GAAP
- -
54.43%
76.78%
Sales/Revenue/Turnover
- -
14.53%
14.34%
Total Cash Common Dividend
- -
- -
20.01%

Semi-annual Revenue

INR

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
2,451
2025
- -
- -
3,181
2026
- -
- -
3,637

Semi-annual Earnings Per Share

INR

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
5.72
2025
- -
- -
5.97
2026
- -
- -
10.55

Semi-annual Dividends Per Share

INR

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
0.65
2025
- -
- -
0.5
2026
- -
- -
0.6
Similar Companies
UPL Limited (NSE:UPL)
Mosaic Company (The) (NYSE:MOS)
CF Industries Holdings, Inc. (NYSE:CF)
PhosAgro (MOEX:PHOR)
Abou Kir Fertilizers & Chemical Industries Co. (EGX:ABUK)
Misr Fertilizers Production Company MOPCO (EGX:MFPC)
Business
Aristo Bio-Tech and Lifescience Limited (ARISTO-SM.NS), an India-based agrochemical company founded in 2005 and headquartered at E-24-25-26, GIDC Estate, Manjusar, Vadodara, Gujarat, manufactures, formulates, supplies, packages and provides contract manufacturing job work services for pesticides and agrochemicals including insecticides such as Abamectin 1.9% EC, Acephate 75% SP and 95% SG, Alpha-Cypermethrin 5-10% EC/SC, Bifenthrin 2.5-10% EC/SC/CS, Chlorpyrifos 20-48% EC, Cypermethrin 5-40% EC, Emamectin Benzoate 5% SG and 1.9% EC, Fipronil 5% SC and 80% WG, Imidacloprid 30.5% SC and 70% WG, Lambda-Cyhalothrin 2.5-10% EC/WP/CS, Thiamethoxam 25% WG and 75% SG; herbicides and weedicides such as 2,4-D Amine Salt 58% SL and Ethyl Ester 38% EC, Atrazine 50-80% WP, Glyphosate 5-20.2% SL, Pendimethalin 30-38.7% EC/CS, Pretilachlor 50% EC; fungicides including Azoxystrobin 23% SC and various combinations with Tebuconazole, Carbendazim 50% WP, Mancozeb 75% WG/WP and 45.5% SC, Propiconazole 13.9% EC, Tebuconazole 25.9-38.39% EC/SC; and plant growth regulators such as Ethephon 39% SL, Gibberellic Acid 0.186% SP and Paclobutrazol 23-40% SC, with 257 products registered with CIB&RC for domestic sales across 20 Indian states and exports to over 15 countries including Australia, Bangladesh, Germany, Kenya, South Africa, UAE and Vietnam. The ISO 9001:2015-certified company serves Indian and multinational clients such as Syngenta India Ltd, UPL Sustainable Agro Solutions Ltd, Monsanto India Ltd, Jubilant Agri & Consumer Products Ltd and Meghmani Organics Ltd through its formulation and packaging facility equipped for separate production lines to prevent contamination. In FY25 ended March 2025, Aristo Bio-Tech reports revenue of Rs 318 crore, up 30% from Rs 245 crore in FY24, with profit after tax at Rs 4.06 crore amid capacity expansions that increased depreciation by Rs 1 crore; recent developments include securing agrochemical purchase orders worth over Rs 14 crore in September-October 2025 for execution by late October.